Thread: Ingen Technologies Inc. - IGNT

Ingen to Seek 5 to 7 Cents a Share On Future Buyout
Press Release
Source: Ingen Technologies, Inc.
On Tuesday June 30, 2009, 4:15 pm EDT

YUCAIPA, Calif., June 30, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company would seek a 5 to 7 cents a share on a buyout or merger.

"We have turned this company around and it has been awhile in coming; but we are finally in the home stretch heading towards profitability. With this turnaround Ingen would entertain any bidders between 5 and 7 cents," stated Thomas Neavitt, Chief Financial Officer.

"We are evaluating various investment bankers and have not ruled out a possible acquisition or merger. We are committed in doing our very best to enhance shareholder value and at the same time increase corporate growth and earnings," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

About Oxyview:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Ingen Technologies,Inc. - Home

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact:
Ingen Technologies, Inc.Chris Wirth909-790-7180info@ingen-tech.comwww.INGEN-TECH.COM

IGNT provided some great flipping opportunities again today Congrats to all who got in. Support is the 20 day MA line of .0086 and .007 Resistance is .01 .02 .028 and a possible test of .08

IGNT 'BULL FLAG' stock video chart - enjoy and watch for a move!

IGNT Stock Video Chart - BULL FLAG

Originally Posted by Technical_Indicator

IGNT 'BULL FLAG' stock video chart - enjoy and watch for a move!

IGNT Stock Video Chart - BULL FLAG

IGNT HUGE BUYOUT NEWS!!! .05 to .07 cent offer?? wow

Ingen to Seek 5 to 7 Cents a Share On Future Buyout
Ingen to Seek 5 to 7 Cents a Share On Future Buyout

YUCAIPA, Calif., June 30, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company would seek a 5 to 7 cents a share on a buyout or merger.

"We have turned this company around and it has been awhile in coming; but we are finally in the home stretch heading towards profitability. With this turnaround Ingen would entertain any bidders between 5 and 7 cents," stated Thomas Neavitt, Chief Financial Officer.

"We are evaluating various investment bankers and have not ruled out a possible acquisition or merger. We are committed in doing our very best to enhance shareholder value and at the same time increase corporate growth and earnings," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

About Oxyview:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Ingen Technologies,Inc. - Home

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

CONTACT: Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
Ingen Technologies,Inc. - Home

Ingen Ahead of Schedule With Product Distribution and Debt Reduction
Press Release
Source: Ingen Technologies, Inc.
On Wednesday July 1, 2009, 3:15 pm EDT
YUCAIPA, Calif., July 1, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company is ahead of schedule with the debt reduction program, and with export product expansion and distribution.

The company implemented a debt reduction program in March-2009 with efforts focused on operational debts accrued during 2008. To date, the company has paid down all operational debts that were accrued in 2008. "These were debts that we expected to pay off by the end of August-2009; however, we have tightened our belts and paid them off 60 days early," stated Thomas J. Neavitt, Chief Financial Officer. In addition, the company has heavily invested in the marketing and advertising of the new Oxyview Nasal Cannula, using effective publication sources such as COPD Digest and MedCo Forum.

Further, the company is also ahead of schedule with their ISO Certification for export marketing and distribution of their Oxyview product line. Since the introduction of the new Oxyview Nasal Cannula "All-In-One" last week, the company has received hundreds of new distributor inquiries and is now evaluating all of the new distributors. "Ingen is receiving 10-20 new distributor inquiries daily, and this is a difficult process involving due diligence. We want distributors that have been in business for at least 5 years, and have a solid home oxygen patient market in their territory," stated Christopher Wirth, Chief Operations Officer.

"We are all very pleased with the direction this company has taken: reducing our debt, increasing sales and distribution worldwide, and our commitment to our shareholders and their investment. All of these activities play a role in the success and future of this company. We expect to stay ahead of schedule and prosper in the very near future," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

About Oxyview:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S. and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Ingen Technologies,Inc. - Home

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact:
Ingen Technologies, Inc.Chris Wirth909-790-7180info@ingen-tech.comwww.ingen-tech.com

Ingen Looks At Acquiring Comfort Medical Supply
Press Release
Source: Ingen Technologies, Inc.
On Monday July 6, 2009, 4:37 pm EDT
YUCAIPA, Calif., July 6, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company is interested in acquiring Comfort Medical Supply, Inc.

Comfort Medical Supply is located in Calimesa, California, and is a six year old business that provides medical equipment and supplies to the local area. Comfort Medical Supply has made a purchase offer of $39,000, with $100,000 of inventory and with annual sales of $200,000. Comfort Medical Supply has recently made improvements to the store for better visibility while the new shopping center nears completion. There is no debt and the sale will be finalized in 30 days. The company will acquire immediately receive the equity benefits and future opportunity of this acquisition.

"Ingen needs to take advantage of the various opportunities our economy has to offer while we have some excess cash to invest. Our research shows that there are thousands of small medical supply stores for sale due to changes in Medicare and economical changes. Our management believes that acquiring some of these smaller medical suppliers will allow us to better manage and improve sales as well as build the company asset base as a part of our plan to return as a reporting company and on the OTCBB," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

About Ingen Technologies/Oxyview:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Ingen Technologies,Inc. - Home

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact:
Ingen Technologies, Inc.Chris Wirth909-790-7180info@ingen-tech.comwww.ingen-tech.com

Thanks Jav IGNT Back on radar here.

Hearingpossible news out after the close today...Company positioning itself to explode tomorrow!

Letter to Shareholders From Chairman of Ingen Technologies, Inc.
Press Release
Source: Ingen Technologies, Inc.
On Wednesday July 8, 2009, 4:15 pm EDT
YUCAIPA, Calif., July 8, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the CEO and Chairman of the Board has made the following statement.

"We are experienced and committed to the success of this company. Ingen Technologies will continue moving forward in directions that is within the best interest of our shareholders. This company holds increased value within its intellectual property, research & development, new medical product lines in the ever expanding senior markets, inventory and other assets. Although we are receiving serious interest from larger companies regarding a buyout, we must also look at current opportunities in acquisitions of our own that can add value to our product line and our bottom line. The acquisition of Comfort Medical Supply, Inc., although small, would increase our net asset value, decrease our debt, add more revenues, and increase our acquisition value for any future buyout. This acquisition would add an immediate $300,000 to our bottom line, and increase a current buyout price to 10 cents per share. These types of opportunities are rare. Even more important, in the past 8 days we have received hundreds of orders of our new Oxyview Nasal Cannula. These new sales are currently supported by our website and word of mouth, and we expect even a much greater increase in new sales when the advertising programs begin this September, 2009 with COPD Digest and Medco Forum. Again, this could add value to our share price even more for any future buyout. With all of this in mind, the company is moving as quickly as possible to increase our distribution network and complete the ISO Certifications to market and sell our new products in qualified export countries. Ingen will be ISO certified within the next several months, and the Emergo Group is working on identifying and qualifying the necessary large distributors for China, Japan, Canada, Europe and Australia. The company and its management are comprehensively focused on new product sales and we recognize the importance of increased revenues and earnings. Ingen is an undervalued pink-sheet stock, and to increase the value we must increase our own revenues and recognize the value of any recent acquisitions that would strategically position Ingen with a higher buyout price. The company is committed to the success of Ingen and all of its shareholders. With everything combined, the company expects strong growth and increased earnings in the near future," stated Scott R. Sand, Chief Financial Officer and Chairman of the Board.

About Ingen Technologies/Oxyview:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

Ingen Technologies,Inc. - Home

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact:
Ingen Technologies, Inc.Chris Wirth909-790-7180info@ingen-tech.comwww.INGEN-TECH.COM

Support is the 50 MA line of .0053 followed by .0047 which must hold imo First major resistance is .007 followed by the 20 MA line of .009 .01 and a possible test of .02